Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement. (RECORD 3)

October 24, 2014 updated by: Bayer

RECORD 3 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a Controlled., Double-blind, Randomized Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.

The purpose of this study is to assess if 10 mg Bay 59-7939, taken once daily as a tablet, is safe and prevents blood clot which may form after a knee replacement operation.

Study Overview

Study Type

Interventional

Enrollment (Actual)

2531

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Wien, Austria, 1140
    • Oberösterreich
      • Linz, Oberösterreich, Austria, 4010
    • Steiermark
      • Graz, Steiermark, Austria, 8036
    • Tirol
      • Innsbruck, Tirol, Austria, 6020
      • Antwerpen, Belgium, 2020
      • Hasselt, Belgium, 3500
      • Liege, Belgium, 4000
      • Merksem, Belgium, 2170
      • Pellenberg, Belgium, 3212
      • Reet, Belgium, 2840
      • Roeselare, Belgium, 8800
    • British Columbia
      • Penticton, British Columbia, Canada, V2A 5C8
    • New Brunswick
      • St. John, New Brunswick, Canada, E2L 4L2
    • Ontario
      • Burlington, Ontario, Canada, L7R 4C4
      • Kitchener, Ontario, Canada, N2G 1G3
      • Oakville, Ontario, Canada, L6J 3M5
      • Oshawa, Ontario, Canada, L1G 2B9
      • Ottawa, Ontario, Canada, K1Y 4E9
      • Peterborough, Ontario, Canada, K9J 7C6
      • Scarborough, Ontario, Canada, M1E 4B9
      • Windsor, Ontario, Canada, N9A 1E1
      • Beijing, China, 100044
      • Beijing, China, 100853
      • Beijing, China, 100035
      • Shanghai, China, 200032
      • Shanghai, China, 200233
      • Shanghai, China, 200025
      • Bogotá, Colombia
      • Cali, Colombia
      • Medellín, Colombia
      • Brno, Czech Republic, 62500
      • Chomutov, Czech Republic, 430 01
      • Havlickuv Brod, Czech Republic, 580 01
      • Jihlava, Czech Republic, 586 01
      • Kolin, Czech Republic, 280 00
      • Pardubice, Czech Republic, 530 03
      • Plzen, Czech Republic, 304 60
    • Tschechien
      • Praha 8, Tschechien, Czech Republic, 180 81
      • Frederiksberg, Denmark, 2000
      • Hellerup, Denmark, 2900
      • Herlev, Denmark, 2730
      • Hørsholm, Denmark, DK-2970
      • Silkeborg, Denmark, 8600
      • Bois-guillaume, France, 76230
      • Clermont Ferrand, France, 63050
      • Lievin, France, 62806
      • Marseille, France, 13008
      • Monaco, France, 98000
      • Nantes Cedex 2, France, 44277
      • Nice, France, 06002
      • Nice, France, 06000
      • Paris, France, 75674
      • Paris Cedex 14, France, 75877
      • Paris Cedex 19, France, 75019
      • Paris Cedex 20, France, 75960
      • Soyaux, France, 16800
      • Vandoeuvre Les Nancy, France, 54511
      • Bremen, Germany, 28205
    • Baden-Württemberg
      • Bad Mergentheim, Baden-Württemberg, Germany, 97980
      • Rheinfelden, Baden-Württemberg, Germany, 79618
    • Bayern
      • Fürth, Bayern, Germany, 90766
      • Garmisch-Partenkirchen, Bayern, Germany, 82467
      • Würzburg, Bayern, Germany, 97080
    • Brandenburg
      • Sommerfeld, Brandenburg, Germany, 16766
    • Hessen
      • Frankfurt, Hessen, Germany, 60528
      • Frankfurt, Hessen, Germany, 65929
    • Nordrhein-Westfalen
      • Düsseldorf, Nordrhein-Westfalen, Germany, 40225
      • Witten, Nordrhein-Westfalen, Germany, 58448
      • Beer Sheva, Israel, 84101
      • Haifa, Israel, 31096
      • Holon, Israel, 58100
      • Kfar Saba, Israel, 44281
      • Tel Aviv, Israel, 64239
      • Tel Hashomer, Israel, 52621
      • Zerifin, Israel, 70300
      • Bologna, Italy, 40136
      • Firenze, Italy, 50139
      • Lecco, Italy, 23900
      • Padova, Italy, 35127
      • Parma, Italy, 43100
      • Roma, Italy, 00168
      • Udine, Italy, 33100
      • Varese, Italy, 21100
    • Milano
      • San Donato Milanese, Milano, Italy, 20097
    • Padova
      • Abano Terme, Padova, Italy, 35031
    • Perugia
      • Gubbio, Perugia, Italy, 06024
    • Sassari
      • Alghero, Sassari, Italy, 07041
    • Chihuahua
      • Chihuahua, Chih., Chihuahua, Mexico, 31000
    • Jalisco
      • Guadalajara, Jalisco, Mexico, 44280
    • Sonora
      • Hermosillo, Sonora, Mexico, 83000
      • Amsterdam, Netherlands, 1105 AZ
      • Hilversum, Netherlands, 1213 XZ
      • Hoofddorp, Netherlands, 2134 TM
      • Leiden, Netherlands, 2334 CK
      • Nijmegen, Netherlands, 6522 JV
      • OSS, Netherlands, 5342 BT
      • Zwolle, Netherlands, 8011 JW
      • Elverum, Norway, 2409
      • Gjövik, Norway, 2819
      • Kongsvinger, Norway, 2212
      • Lillehammer, Norway, 2609
      • Namsos, Norway, 7800
      • Callao, Peru, CALLAO 2
      • Lima, Peru, Lima 11
      • Lima, Peru, Lima 1
      • Bialystok, Poland, 15-276
      • Bydgoszcz, Poland, 85-094
      • Gdansk, Poland, 80-803
      • Krakow, Poland, 31-826
      • Lodz, Poland, 91-002
      • Lublin, Poland, 20-090
      • Lublin, Poland, 20-718
      • Szczecin, Poland, 71-252
      • Warszawa, Poland, 02-637
      • Warszawa, Poland, 00-909
    • Freestate
      • Bloemfontein, Freestate, South Africa, 9300
    • Gauteng
      • Johannesburg, Gauteng, South Africa, 2132
      • Pretoria, Gauteng, South Africa, 0084
      • Pretoria, Gauteng, South Africa
      • Pretoria, Gauteng, South Africa, PRETORIA
      • Randburg, Gauteng, South Africa, 2125
    • Kwa Zulu-Natal
      • Newcastle, Kwa Zulu-Natal, South Africa, 2940
    • KwaZulu Natal
      • Durban, KwaZulu Natal, South Africa, 4030
    • Western Cape
      • Somerset West, Western Cape, South Africa, 7130
      • Worcester, Western Cape, South Africa, 6850
      • Barcelona, Spain, 08036
      • Barcelona, Spain, 08035
      • Barcelona, Spain, 08006
      • Castellón de la Plana, Spain, 12004
      • Jaén, Spain, 23007
      • Madrid, Spain, 28040
      • Pamplona, Spain, 31008
      • Valencia, Spain, 46010
    • Barcelona
      • Badalona, Barcelona, Spain, 08916
    • Madrid
      • Alcorcón, Madrid, Spain, 28922
      • Falköping, Sweden, 521 85
      • Göteborg, Sweden, 416 85
      • Halmstad, Sweden, 301 85
      • Hässleholm, Sweden, 281 25
      • Jönköping, Sweden, 551 85
      • Kungälv, Sweden, 442 83
      • Lidköping, Sweden, 531 85
      • Varberg, Sweden, 432 81

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:- Male and female patients aged 18 years or above- Patients scheduled for elective total knee replacement Exclusion Criteria:- Active bleeding or high risk of bleeding contraindicating treatment with LMWH- Contraindication listed in the labeling or conditions precluding subject treatment with enoxaparin or requiring dose adjustment (e.g. severe renal impairment, please refer to the local label of enoxaparin in your country)- Conditions prohibiting bilateral venography (e.g. amputation of 1 leg, allergy to contrast media)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Arm 2
Syringe of enoxaparin at a dose of 40 mg for 13 +/- 2 days
Experimental: Arm 1
10 mg rivaroxaban (tablet) once daily administered for 13 +/- 2 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Composite endpoint of total VTE i.e.: Any DVT (proximal and/or distal), Non fatal PE, Death of all causes
Time Frame: Treatment period: up to Day 13+/-4
Treatment period: up to Day 13+/-4

Secondary Outcome Measures

Outcome Measure
Time Frame
Treatment-emergent major bleedings
Time Frame: From first dose of double-blind study medication to up to two days after last dose of double-blind study medication
From first dose of double-blind study medication to up to two days after last dose of double-blind study medication
Incidence of the composite endpoint comprising proximal DVT, non-fatal PE and VTE- related death (major VTE)
Time Frame: Treatment period: up to Day 13+/-4
Treatment period: up to Day 13+/-4
Incidence of symptomatic VTE (DVT, PE)
Time Frame: Treatment period: up to Day 13+/-4
Treatment period: up to Day 13+/-4
Incidence of DVT (total, proximal, distal)
Time Frame: Treatment period: up to Day 13+/-4
Treatment period: up to Day 13+/-4
Incidence of symptomatic VTE during follow-up
Time Frame: Follow-up period: following 13+/-4 days
Follow-up period: following 13+/-4 days
The composite endpoint comprising major VTE and treatment-emergent major bleeding
Time Frame: For major VTE, treatment period: up to Day 13+/-4 ; for major bleeding, from first dose of double-blind study medication to up to two days after last dose of double-blind study medication
For major VTE, treatment period: up to Day 13+/-4 ; for major bleeding, from first dose of double-blind study medication to up to two days after last dose of double-blind study medication
Incidence of the composite endpoint that results from the primary endpoint by substituting VTE related death for all death
Time Frame: Treatment period: up to Day 13+/-4
Treatment period: up to Day 13+/-4
Incidence of the composite endpoint that results from major VTE by substituting all cause mortality for VTE-related death
Time Frame: Treatment period: up to Day 13+/-4
Treatment period: up to Day 13+/-4

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2006

Primary Completion (Actual)

January 1, 2007

Study Completion (Actual)

January 1, 2007

Study Registration Dates

First Submitted

August 8, 2006

First Submitted That Met QC Criteria

August 8, 2006

First Posted (Estimate)

August 9, 2006

Study Record Updates

Last Update Posted (Estimate)

October 27, 2014

Last Update Submitted That Met QC Criteria

October 24, 2014

Last Verified

October 1, 2014

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe